Brain-Computer Interface (BCI)

Definition and Technical Overview

A brain-computer interface (BCI) is a system that establishes a direct communication pathway between the brain's electrical activity and an external computing device. BCIs decode neural signals, patterns of electrical impulses generated by neurons, and translate them into commands that can control computers, robotic limbs, communication devices, or other technologies. The technology also encompasses the reverse pathway: delivering information to the brain through electrical or optical stimulation to restore sensory function or modulate neural activity.

BCIs are categorised by their degree of invasiveness. Non-invasive BCIs use electroencephalography (EEG) or functional near-infrared spectroscopy (fNIRS) to detect brain signals through the skull, offering safety but limited spatial resolution and signal quality. Partially invasive systems place electrodes on the brain's surface (electrocorticography, or ECoG), providing better signal quality without penetrating brain tissue. Fully invasive BCIs insert microelectrode arrays directly into brain tissue, achieving the highest signal resolution but requiring neurosurgery and carrying risks of infection, immune response, and long-term electrode degradation.

K-Moonshot Mission 2: Brain Implant Commercialisation

K-Moonshot Mission 2 targets the commercialisation of brain implant technology, one of the most technically and regulatorily challenging missions in the entire K-Moonshot programme. The mission aims to develop clinically viable BCIs for medical applications including restoration of motor function for paralysis patients, treatment of neurological disorders such as drug-resistant epilepsy and treatment-resistant depression, and enhancement of communication capabilities for patients with locked-in syndrome or advanced neurodegenerative diseases.

The mission's scope extends beyond device development to encompass the full commercialisation pathway: clinical trials, regulatory approval through Korea's Ministry of Food and Drug Safety (MFDS), manufacturing scale-up, healthcare system integration, and post-market surveillance. This end-to-end approach reflects the recognition that BCI technology has been demonstrated in research settings for decades but has struggled to transition from laboratory prototypes to commercial medical devices available to patients.

Korea's Neurotechnology Landscape

Korea's BCI research ecosystem is anchored in its leading research universities and government institutes. KAIST's Department of Bio and Brain Engineering has produced internationally recognised research in neural signal processing, brain-inspired computing, and implantable device engineering. Seoul National University's Biomedical Engineering department has advanced flexible electrode technologies that may improve long-term implant biocompatibility. KIST's Brain Science Institute conducts fundamental neuroscience research that underpins BCI development.

Korea's industrial capabilities in semiconductor fabrication, advanced packaging, and miniaturised electronics provide critical manufacturing foundations for BCI device production. The neural interfaces of the future will require application-specific integrated circuits (ASICs) for signal processing, biocompatible encapsulation materials, wireless power and data transmission systems, and precision microelectrode fabrication, all areas where Korean industry possesses world-class capabilities. Samsung's semiconductor division, in particular, has the process technology to fabricate the ultra-low-power neural signal processing chips that implantable BCIs demand.

Global Competition and Context

The global BCI landscape has been energised by Neuralink, Elon Musk's neurotechnology company, which implanted its first human patient in January 2024. Neuralink's N1 device uses 1,024 electrodes inserted into the motor cortex by a robotic surgeon, enabling paralysed patients to control computer cursors through thought. BrainGate, a consortium of US academic medical centres, has demonstrated BCI control of robotic arms and communication devices in clinical trials spanning more than a decade. Synchron, an Australian-American company, has developed a less invasive stent-based BCI (Stentrode) that is inserted through blood vessels, avoiding open brain surgery.

Chinese institutions have also accelerated BCI research, with Tsinghua University demonstrating a wireless BCI system and multiple Chinese companies pursuing commercial development. The European Union's Human Brain Project, while broader in scope than BCI specifically, has generated foundational neuroscience insights applicable to interface development.

Korea's differentiated approach under Mission 2 does not attempt to replicate Neuralink's consumer-oriented ambitions. Instead, it focuses on medical-grade devices with clear clinical pathways, an approach more aligned with BrainGate's methodical clinical trial model but with the industrial manufacturing capability to scale production once regulatory approval is achieved.

Regulatory and Ethical Considerations

Brain implant commercialisation faces extraordinary regulatory scrutiny. The MFDS, Korea's equivalent of the US FDA, classifies brain implants as Class III medical devices requiring the most rigorous pre-market approval process. Clinical trials must demonstrate safety and efficacy across multiple phases, a process that typically spans five to ten years for novel implantable devices. The regulatory timeline is a primary driver of Mission 2's long-range planning horizon extending to 2035.

Ethical considerations are equally significant. Brain implants raise questions about informed consent for patients with communication impairments, data privacy for directly recorded neural activity, cognitive liberty and the right to mental privacy, equitable access to potentially life-changing but expensive technology, and the long-term psychological effects of direct brain-device coupling. Korea's AI ethics framework and bioethics committees are developing governance principles specific to neurotechnology, recognising that BCI regulation requires frameworks beyond those established for conventional medical devices.

Technical Frontiers

Several technical advances are necessary to achieve the commercial viability targeted by Mission 2. Electrode longevity remains a primary challenge: the brain's immune response gradually encapsulates implanted electrodes in scar tissue, degrading signal quality over months to years. Research into flexible, biocompatible electrode materials, including graphene-based and polymer substrates, aims to minimise immune response and extend device lifetimes to the decades required for chronic implants.

Wireless power and data transmission must achieve sufficient bandwidth to handle thousands of simultaneous neural channels while consuming minimal power and generating negligible heat within brain tissue. Advanced signal processing algorithms, increasingly incorporating AI and machine learning, are needed to decode complex neural patterns in real time with high accuracy. Korea's strengths in AI accelerator chip design and low-power semiconductor engineering are directly applicable to these challenges.